NKG2A Antibody CDR Optimization for Stronger NK Cell Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing antibodies targeting NKG2A have limitations in terms of activity and affinity, necessitating the development of specific antibodies with stronger activity and higher affinity to modulate NK cell function and prevent autoimmune responses.

Innovation Solution

Development of NKG2A antibodies with specific heavy and light chain variable region CDR sequences, including derivatives with added, deleted, or modified amino acids, to enhance binding affinity and specificity, allowing for applications in tumor immunotherapy and autoimmune disease treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing antibodies targeting NKG2A are used, then basic immune modulation function is achieved, but activity and affinity are insufficient

Engineering Contradiction:

Improvebinding affinityVSAvoidNK cell activation activity

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent applies parameter changes by systematically modifying the CDR sequences of the antibody to optimize binding affinity. Specific amino acid substitutions in VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 regions were made to enhance both affinity for NKG2A and functional activity in activating NK cells, resolving the contradiction between basic function and enhanced performance

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies local quality by making specific modifications to the CDR regions while maintaining the overall antibody structure. The variable regions were optimized with specific amino acid changes at critical positions to enhance binding and activation properties, allowing different parts of the antibody to have specialized functions for affinity and activity

Inventive Principle:

Principle #3Local quality

2Reliability

If antibody sequences are optimized for higher affinity, then binding strength increases, but development complexity increases

Engineering Contradiction:

Improvebinding affinityVSAvoidantibody sequence complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the antibody optimization into distinct modular components: separate optimization of VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 regions. Each CDR was independently designed and optimized, allowing systematic improvement of affinity without overwhelming complexity in the overall design process

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS12534526B2NKG2A antibody, preparation method therefor and application thereof

Publication Date: 2026.01.27 SHANGHAI HYAMAB BIOTECH CO LTD

AI summary

Provided are an antibody targeting NKG2A, a preparation method therefor and use thereof. Specifically, provided is a new mouse or humanized monoclonal antibody targeting NKG2A, and a method for preparing the monoclonal antibody. The monoclonal antibody can bind to an NKG2A antigen with high specificity, and has high affinity and significant activities such as anti-tumor activity.